The answer so far
“Fat dissolving”, “fat burning” and “weight loss” can describe different things. A local injection aims to change a particular area; fat burning means using fat as fuel; weight loss means a lower scale weight. A medicine that affects appetite works differently again. The product and the outcome—not the slogan—tell you what is being claimed.145
On this page
Fat-dissolving injections, fat burning and weight loss: what is the difference? Choose a step to explore this subject in more detail.
Start with the result being sought
One person may want to understand changes in body weight; another may be asking about fullness under the chin. A change in a small area is not necessarily meaningful weight loss, and an appearance preference does not by itself establish a medical problem. Define the goal before comparing products. For the distinction between stored fat, fat used as fuel and the number on a scale, see fat burning, fat loss and weight loss.41
- Fat burningUsing fat as fuel is a normal process; one moment does not establish lasting fat loss.
- Appetite medicinesSpecific products act on appetite signals and are studied for particular conditions.
- AOD-9604A growth-hormone fragment studied for weight loss; an oral trial did not establish a clear benefit.
- Local fat dissolutionA particular deoxycholic-acid medicine targets cells under the chin, not body weight.
What is a local fat-dissolving injection?
The US prescription product Kybella contains deoxycholic acid and is intended to break down fat cells at the treated site under the chin. Its approved purpose is improving the appearance of moderate-to-severe fullness from fat in that area in adults, not treating obesity. It is not a peptide. A local product should not be assumed to affect deeper abdominal fat, whole-body metabolism or appetite. See Kybella’s evidence and risks.1
How is that different from an appetite medicine?
Some prescription medicines affect appetite and food intake through hormone signalling. For example, semaglutide has different named products for different indications. Trials of an authorised product measure outcomes in specified patients over time; a cosmetic under-chin study measures something else. Neither type can be substituted for the other, and a prescription medicine’s indication depends on the product and country. Explore the semaglutide product guide.51
Where does AOD-9604 fit?
AOD-9604 is a peptide related to a fragment of growth hormone and has been marketed for fat loss. In the large oral weight study described by the FDA, the primary comparison did not show a statistically significant weight-loss difference from placebo. This does not establish the effect of an injection, and it is not evidence that AOD is the same as deoxycholic acid. Read what the AOD study actually found.61
Does injecting near the stomach reach visceral fat?
Fat under the skin and visceral fat deeper inside the abdomen are different. A claim that an injection changes an area under the skin does not establish an effect on fat surrounding internal organs. Even a change in visceral-fat imaging does not automatically demonstrate a particular health outcome. Our guide to the two types of abdominal fat explains what can and cannot be inferred.71
How should I assess an online offer?
Ask for the complete product name and ingredients, who makes it, who would administer it, the exact body area and the studies on that product and outcome. A certificate or the phrase “medical grade” is not proof of approval, sterility or clinical benefit. In the US, the FDA has reported injuries associated with unapproved injectable fat-dissolving products. The legal and regulatory position can differ elsewhere; consult the relevant local regulator and a qualified clinician.32
What if someone feels unwell afterwards?
After an injection, worsening pain, marked swelling, skin changes or other concerning symptoms merit prompt medical advice. The FDA advises medical attention for adverse events following Kybella and highlights symptoms including facial weakness and swallowing difficulty. Severe symptoms or difficulty breathing require urgent local emergency care. Tell the clinician the exact product, site and when it was used.23
Sources, kept close.
Selected supporting sources; this is not a complete literature review.
- Kybella (deoxycholic acid) prescribing information, revised September 2026US Food and Drug Administration · Official product label
- FDA Approves Additional Information in Labeling for Kybella Warning of Adverse Reactions Associated with Unapproved UseUS Food and Drug Administration · Regulatory safety communication
- Using Fat-Dissolving Injections That Are Not FDA Approved Can Be HarmfulUS Food and Drug Administration · Consumer safety communication
- Overweight and obesity in adultsNational Institutes of Health · Public health overview
- Wegovy (semaglutide) prescribing informationU.S. Food and Drug Administration · Approved product label
- AOD-9604 related bulk drug substances: FDA advisory committee briefingUS Food and Drug Administration · 2024 US regulator briefing; obesity evaluation and search limitations
- Patterns of Abdominal Fat Distribution: The Framingham Heart StudyDiabetes Care / PubMed Central · Observational population study using CT